The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
ACP3 targeting PET radiotracer is promising as an excellent imaging agent applicable to prostate cancer. In this research, subjects with prostate cancer or highly suspected recurrence detection underwent contemporaneous ACP3 PET/CT and standard-of-care imaging (PSMA/FDG PET/CT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and 68Ga-PSMA PET/CT were recorded by visual interpretation. The diagnostic accuracy of ACP3 PET/CT was calculated and compared to standard-of-care imaging.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (PSMA/FDG) and ACP3, and undergoes PET/CT imaging within the specified time.
The First Affliated Hospital of Guilin Medical University
Guilin, Guangxi, China
RECRUITINGDiagnostic efficacy
The sensitivity, specificity, and accuracy of standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
Time frame: 3 year
Number of lesions
The numbers of positive primary and metastatic lesions of standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT were recorded by visual interpretation.
Time frame: 3 year
SUV
Standardized uptake value (SUV) of standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT for each target lesion of subject or suspected primary tumor or/and metastasis.
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.